Abstract: Disclosed are a method and device for controlling the state switching of a fluid torque converter, a vehicle and a storage medium, the method including: obtaining a target instruction when the torque converter of the vehicle is in a locked state, the target instruction triggering a change in the torque transmission direction of a transmission system of the vehicle; obtaining a state parameter, and determining whether the current vehicle is in a target operating condition according to the state parameter; and if the current vehicle is in the target operating condition, switching the fluid torque converter to an open state, and switching the torque converter back to the locked state after maintaining the open state for a preset period of time.

Abstract: Provided are a compound of formula (I), a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic thereof, or a pharmaceutical composition comprising same, and use thereof as a ketohexokinase inhibitor in the preparation of drugs for treating related diseases. Each group in formula (I) is as defined in the description.

Abstract: Disclosed is a high-precision dynamic real-time 360-degree omnidirectional point cloud acquisition method based on fringe projection. The method comprises: firstly, by means of the fringe projection technology based on a stereoscopic phase unwrapping method, and with the assistance of an adaptive dynamic depth constraint mechanism, acquiring high-precision three-dimensional (3D) data of an object in real time without any additional auxiliary fringe pattern; and then, after a two-dimensional (2D) matching points optimized by the means of corresponding 3D information is rapidly acquired, by means of a two-thread parallel mechanism, carrying out coarse registration based on Simultaneous Localization and Mapping (SLAM) technology and fine registration based on Iterative Closest Point (ICP) technology.

Abstract: A solid conductor including: a compound represented by Formula 1, a compound represented by Formula 2, or a combination thereof Li1+x+y-zTa2-xMxP1-yQyO8-zXz??Formula 1 wherein, in Formula 1, M is an element having an oxidation number of +4, Q is an element having an oxidation number of +4, X is a halogen, a pseudohalogen, or a combination thereof, and 0?x?2, 0?y<1, and 0?z?2, except that cases i) x and y and z are simultaneously 0, ii) M is Hf, X is F, x is 1, y is 0, and z is 1, iii) M is Hf, X is Cl, x is 2, y is 0, and z is 2, and iv) M is Hf, X is F, x is 2, y is 0, and z is 2, Li1+x+y-zTa2-xMxP1-yQyO8·zLiX??Formula 2 wherein, in Formula 2, M is an element having an oxidation number of +4, Q is an element having an oxidation number of +4, X is a halogen, a pseudohalogen, or a combination thereof, and 0?x?2, 0?y<1, and 0?z?2, except that cases i) x and y and z are simultaneously 0, ii) M is Hf, X is F, x is 1, y is 0, and z is 1, iii) M is Hf, X is Cl, x is 2, y is 0, and z

Abstract: A calibration method for fringe projection systems based on plane mirrors. Firstly, two mirrors are placed behind the tested object. Through the reflection of mirrors, the camera can image the measured object from the front and other two perspectives, so as to obtain 360-degree two-dimensional information of the measured object. The projector projects three sets of phase-shifting fringe patterns with frequencies of 1, 8, and 64. The camera captures the fringe image to obtain an absolute phase map with a frequency of 64 by using the phase-shifting method and the temporal phase unwrapping algorithm. By using the calibration parameters between the projector and the camera, the absolute phase map can be converted into three-dimensional information of the measured object. Then, the mirror calibration is realized by capturing a set of 3D feature point pairs, so that the 3D information from different perspectives is transformed into a unified world coordinate system.

Abstract: Providing a B3 transcription factor gene for simultaneously improving length, strength and elongation of cotton fibers. The cDNA sequence of gene GHFLS in tetraploid upland cotton TM-1 is SEQ ID NO. 1, and the genome sequence is SEQ ID NO. 2; GHFLS contains a non-synonymous mutation SNP, located at 1391 bp of the coding region with the base changing from A to G and the corresponding amino acid changing from Lys to Arg. The GHFLS gene was overexpressed in Arabidopsis thaliana caused a significant reduction in the root length of the T2 generation, demonstrating its important role in the cell elongation mechanism. The fiber quality of the cotton variety (line) with haplotype AA is significantly better than that with haplotype GG. The gene has important research value and application prospect in efficiently identifying high-quality fiber upland cotton varieties, improving cotton fiber quality and cultivating new varieties of high-quality cotton fibers.

Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.

Abstract: Embodiments of this application provide a headset theme adaptation method, so that related information such as a device model and a device identifier of a headset case protective cover can be automatically obtained through multi-end linkage between a mobile phone, a headset, the headset case protective cover, and a cloud server (for example, a server of a cloud theme market), and a headset theme adapted to the protective cover is downloaded and applied based on the related information, to implement personalized experience of headset theme adaptation.

Abstract: A solid conductor including: a compound represented by Formula 1, a compound represented by Formula 2, or a combination thereof Li1+x+y?zTa2?xMxP1?yQyO8?zXz??Formula 1 wherein, in Formula 1, M is an element having an oxidation number of +4, Q is an element having an oxidation number of +4, X is a halogen, a pseudohalogen, or a combination thereof, and 0?x?2, 0?y<1, and 0?z?2, except that cases i) x and y and z are simultaneously 0, ii) M is Hf, X is F, x is 1, y is 0, and z is 1, iii) M is Hf, X is Cl, x is 2, y is 0, and z is 2, and iv) M is Hf, X is F, x is 2, y is 0, and z is 2, Li1+x+y?zTa2?xMxP1?yQyO8·zLiX??Formula 2 wherein, in Formula 2, M is an element having an oxidation number of +4, Q is an element having an oxidation number of +4, X is a halogen, a pseudohalogen, or a combination thereof, and 0?x?2, 0?y<1, and 0?z2, except that cases i) x and y and z are simultaneously 0, ii) M is Hf, X is F, x is 1, y is 0, and z is 1, iii) M is Hf, X is Cl, x is 2, y is 0, and z is 2, and iv)

Abstract: A compound of Formula 1 Li1+(4?a)?Hf2??Ma?(PO4??)3??(1) is disclosed, wherein M is at least one cationic element having a valence of a, wherein 0<???, 1?a?4, and 0???0.1. Also described are an electrolyte composition, a separator, a protected positive electrode, a protected negative electrode, and a lithium battery, each including the compound of Formula 1.

Abstract: A drug-loaded medical device, a preparation method therefor, a drug balloon and a method of preparing a drug coating are disclosed. The medical device or the drug balloon is provided on a surface thereof with a drug coating including a stabilizer and a drug. The stabilizer includes an amphiphilic triblock polymer with hydrophilic segments at both terminals, and the drug coating forms a nano-drug particle suspension in a water-soluble environment. In this way, the prepared nano-drug coating has high drug loading and can deliver the drug in a desirable way. In particular, when it comes into contact with water, the drug can be restored to the original nano size, almost without any particle size increase. This not only avoids the risk of embolism caused by granules, but also enables higher device safety, increased drug uptake and improved therapeutic effects.

Abstract: A convex type guide plate waterwheel energy increasing device with gradually dense holes is provided. The convex type guide plate waterwheel energy increasing device comprises fixed devices, a main diversion plate and auxiliary diversion plates, wherein an upwards convex arc structure is arranged on the top surface of the main diversion plate, gradually dense first through holes are formed in the main diversion plate from the middle to the two ends, the diameters of the first through holes are gradually increased, the auxiliary diversion plates are connected to the two sides of the main diversion plate, second through holes are formed in the auxiliary diversion plates, fixed devices are fixed to the two sides of the auxiliary diversion plates, and the fixed devices are used for fixing the main diversion plate and the auxiliary diversion plates to the riverbed.

Abstract: A computer-implemented method includes receiving a viewer request for playing a video summary of a video, wherein the viewer request includes a length of the video summary, generating the video summary of the viewer-requested length comprising a set of frames selected from the video based on audience reviews of the video, and playing a video stream of the video summary.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: A compound of Formula 1 Li1+(4?a)?Hf2??Ma?(PO4??)3??(1) is disclosed, wherein M is at least one cationic element having a valence of a, wherein 0<???, 1?a?4, and 0???0.1. Also described are an electrolyte composition, a separator, a protected positive electrode, a protected negative electrode, and a lithium battery, each including the compound of Formula 1.

Abstract: The invention discloses a single-frame fringe pattern analysis method based on multi-scale generative adversarial network. A multi-scale generative adversarial neural network model is constructed and a comprehensive loss function is applied. Next, training data are collected to train the multi-scale generative adversarial network. During the prediction, a fringe pattern is fed into the trained multi-scale network where the generator outputs the sine term, cosine term, and the modulation image of the input pattern. Finally, the arctangent function is applied to compute the phase. When the network is trained, the parameters of the network do not need to manually tune during the calculation. Since the input of the neural network is only a single fringe pattern, the invention provides an efficient and high-precision phase calculation method for moving objects.

Abstract: A display panel and manufacturing method therefor and a display device are provided. The display panel includes: a base substrate; an insulation layer arranged at a peripheral area of the base substrate; at least one encapsulation dam arranged on a surface of the insulation layer away from the base substrate, the encapsulation dam being located in the peripheral area of the base substrate and being arranged around the display area; and at least one groove disposed in the insulation layer, a projection of the at least one groove on the base substrate being located within on a projection of the encapsulation dam on the base substrate.

Abstract: The disclosed invention relates to a low-dose celecoxib oral formulation, and a preparation method therefor, which is characterized in that the strength of the formulation is 60-90% of the original strength of the commercial celecoxib product, and the celecoxib formulation with such reduced strength is bioequivalent to the commercial celecoxib product. The celecoxib formulation can be used for the treatment of mild to moderate pain and mild to moderate chronic pain.

Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.